title: [Metastatic renal cell carcinoma: primary and follow-up treatment].
abstract: Systemic treatment of metastatic renal cell carcinoma has changed fundamentally in recent years. So-called targeted therapy gives patients with incurable renal cell cancer the chance of prolonged survival with acceptable quality of life and manageable side effects. Several tyrosine kinase inhibitors and mTOR inhibitors have been evaluated in various clinical settings within prospective trials. Therefore, recent medical guidelines are able to give recommendations for the management of advanced renal cell carcinoma in daily practice. The optimal therapeutic sequence of the available substances has not been defined until now; however recent data recommend the use of a tyrosine kinase inhibitor as the first line treatment. Besides standard treatment, new approaches are currently being evaluated in clinical trials.
authors.affiliation: Klinik für Urologie, Helios Klinikum Erfurt GmbH, Nordhäuser Straße 74, 99089, Erfurt, Deutschland, thomas.steiner@helios-kliniken.de.
authors.forename: T
authors.initials: T
authors.lastname: Steiner
authors.forename: G H
authors.initials: GH
authors.lastname: Mickisch
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary*; D015195:Drug Design; D019317:Evidence-Based Medicine; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D058990:Molecular Targeted Therapy / Q000379:methods*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; C546842:MTOR protein, human; D011505:Protein-Tyrosine Kinases; D058570:TOR Serine-Threonine Kinases